EPS for Enel Americas SA (ADR) (ENIA) Expected At $0.00; Pier Capital Trimmed Sage Therapeutics (SAGE) Stake

May 9, 2017 - By Louis Casey

Analysts expect Enel Americas SA (ADR) (NYSE:ENIA) to report $0.00 EPS on May, 19. About 248,119 shares traded. Enel Americas SA (ADR) (NYSE:ENIA) has risen 20.15% since September 30, 2016 and is uptrending. It has outperformed by 9.49% the S&P500.

Pier Capital Llc decreased Sage Therapeutics Inc (SAGE) stake by 5.12% reported in 2016Q4 SEC filing. Pier Capital Llc sold 6,233 shares as Sage Therapeutics Inc (SAGE)’s stock rose 11.88%. The Pier Capital Llc holds 115,506 shares with $5.90 million value, down from 121,739 last quarter. Sage Therapeutics Inc now has $2.38B valuation. The stock declined 2.99% or $2.04 reaching $66.18 per share. About 95,945 shares traded. SAGE Therapeutics Inc (NASDAQ:SAGE) has risen 48.14% since September 30, 2016 and is uptrending. It has outperformed by 37.48% the S&P500.

Enel Americas S.A., formerly Enersis Americas S.A., through its subsidiaries and jointly controlled entities, is engaged in the electricity generation, transmission and distribution businesses in Chile, Brazil, Colombia, Peru and Argentina. The company has market cap of $11.08 billion. The Firm operates through two divisions: Generation and Transmission, and Distribution. It has a 24.65 P/E ratio. The Company’s Generation and Transmission segment operates through companies, including Central Comercializadora de Energia S.A. ; Central Dock Sud S.A. (Dock Sud); Central Costanera S.A. (Costanera), and Hidroelectrica El Chocon S.A. (El Chocon).

Since November 11, 2016, it had 0 insider buys, and 4 insider sales for $1.37 million activity. $75,885 worth of stock was sold by IGUCHI KIMI on Friday, November 11. Anderson Thomas sold 10,000 shares worth $550,000.

Pier Capital Llc increased Collegium Pharmaceutical Inc stake by 284,929 shares to 329,629 valued at $5.13M in 2016Q4. It also upped Gigamon Inc (NYSE:GIMO) stake by 12,822 shares and now owns 148,166 shares. Evolent Health Inc A was raised too.

Among 10 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. SAGE Therapeutics had 14 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was upgraded by Chardan Capital Markets on Tuesday, February 14 to “Neutral”. On Friday, March 11 the stock rating was initiated by Lake Street with “Buy”. The firm earned “Buy” rating on Thursday, September 3 by Leerink Swann. The firm earned “Outperform” rating on Tuesday, September 13 by Raymond James. Chardan Capital Markets initiated the stock with “Sell” rating in Tuesday, May 24 report. H.C. Wainwright downgraded it to “Neutral” rating and $76 target in Wednesday, February 22 report. The rating was initiated by Goldman Sachs on Wednesday, March 30 with “Neutral”. The stock has “Outperform” rating by BMO Capital Markets on Wednesday, June 29. The stock has “Buy” rating by H.C. Wainwright on Thursday, June 23. The firm has “Buy” rating given on Thursday, September 3 by JP Morgan.